News & Publications
Press Releases
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
● TRB-071, a CD30 agonist antibody designed to activate and expand tissue Tregs and block the CD30L-mediated inflammatory pathway, is progressing through IND-enabling studies ● TRB-051, which is partnered with Lilly, is expected to advance into Phase 2a...
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
Data from human atopic dermatitis (“AD”) skin identify altered tissue Treg programs and support TNFR2 as a regulator of immune homeostasis in tissue TRB-061, a novel TNFR2 agonist, induced selective Treg activity in vitro and pharmacodynamic expansion of...
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist
By selectively augmenting regulatory T cells (“Tregs”), TRB-061 is designed to restore immune balance and promote repair in skin and other barrier tissues Sixteen-week Phase 1b data anticipated in the first half of 2027 SOUTH SAN FRANCISCO, April 29, 2026 – TRex Bio,...
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis The single ascending dose...
TRexBio to Participate in Upcoming Investor Conferences in September
South San Francisco, Calif., September 3, 2025 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that members of its management team will participate in two...
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Safety, pharmacokinetic, and pharmacodynamic data from healthy volunteers anticipated in 1H 2026 Designed to activate and expand tissue regulatory T cells (Tregs) without stimulating effector or innate immune cells, TRB-061 offers a potential new approach to immune...
In the News
Publications
Editorial: Role of tissue-localized regulatory T cells in health and disease
Smith et al., Front Immunol. 2025 Oct 28:16:1718891.
Treg specialization and functions beyond immune suppression
Astarita et al., Clin Exp Immunol. 2023 Mar 16;211(2):176-183.
Tissue regulatory T cells: regulatory chameleons.
Muñoz-Rojas et al., Nat Rev Immunol. 2021 Mar 26;21(9):597-611.
Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome
Jamee et al., J Allergy Clin Immunol Pract. 2020 Sep;8(8):2747-2760.e7.
Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair
Boothby et al., Sci Immunol. 2020 May 1;5(47):eaaz9631.
Treg-Cell Control of a CXCL5-IL-17 Inflammatory Axis Promotes Hair-Follicle-Stem-Cell Differentiation During Skin-Barrier Repair
Mathur et al., Immunity. 2019 Mar 19;50(3):655-667.e4.
Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation
Ali et al., Cell. 2017 Jun 1;169(6):1119-1129.e11.
Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.
Rubtsov et al., Immunity. 2008 Apr;28(4):546-58.
TNFR2 signaling promotes monocytic-MDSC differentiation and production of immunosuppressive mediator
1) Tsuji et al., FEBS Lett. 2026 Apr;600(8):1211-1221.
TNFR2 signalling in inflammatory diseases
Williams et al., Best Pract Res Clin Rheumatol. 2024 May;38(2):101941.
Tregs from human blood differentiate into nonlymphoid tissue–resident effector cells upon TNFR2 costimulation
Mensink et al., JCI Insight. 8;9(5):e172942 March 2024
Colitis-induced upregulation of tumor necrosis factor receptor-2 (TNFR2) terminates epithelial regenerative signaling to restore homeostasis
Sharifkhodaei et al., iScience. 2023 Sep 4;26(10):107829.
IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function
Skartsis et al., Front Immunol. 2021 Dec 23:12:783282.
Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4+Foxp3+ induced Treg cells in vitro and in vivo periphery in autoimmune diseases
Yang et al., Cell Death Dis. 2019 Jan 10;10(1):27.
PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma
Lim et al., Nat Immunol. 2025 Jul;26(7):1074-1086.
Dysregulated T-cell homeostasis and decreased CD30+ Treg proliferating in aplastic anemia
Sun et al., Heliyon. 2024 Aug 3;10(15):e35775.
CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by Vγ4+ γδ T cells
Yue et al., J Autoimmun. 2019 Jul:101:70-85.
A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice
Sun et al., Gastroenterology. 2008 Feb;134(2):447-58.
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease
5) Zeiser et al., Blood. 2007 Mar 1;109(5):2225-33.